Transforming growth factor-β and breast cancer: Cell cycle arrest by transforming growth factor-β and its disruption in cancer by Donovan, Jeffrey & Slingerland, Joyce
Review
Transforming growth factor-b b and breast cancer
Cell cycle arrest by transforming growth factor-b b and its
disruption in cancer
Jeffrey Donovan and Joyce Slingerland
University of Toronto, and Toronto Sunnybrook Regional Cancer Centre and Sunnybrook and
Women’s College Health Sciences Centre, Toronto, Ontario, Canada
Abstract
Altered responsiveness to extracellular signals and cell cycle dysregulation are hallmarks of
cancer. The cell cycle is governed by cyclin-dependent kinases (cdks) that integrate
mitogenic and growth inhibitory signals. Transforming growth factor (TGF)-b mediates G1
cell cycle arrest by inducing or activating cdk inhibitors, and by inhibiting factors required for
cdk activation. Mechanisms that lead to cell cycle arrest by TGF-b are reviewed. Loss of
growth inhibition by TGF-b occurs early in breast cell transformation, and may contribute to
breast cancer progression. Dysregulation of cell cycle effectors at many different levels may
contribute to loss of G1 arrest by TGF-b. Elucidation of these pathways in breast cancer may
ultimately lead to novel and more effective treatments for this disease.
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Introduction
TGF-b is a potent inhibitor of mammary epithelial cell pro-
liferation [1,2] and regulates mammary development in
vivo  [3–5]. Mammary-specific overexpression of TGF-b in
transgenic mice can induce mammary hypoplasia and
inhibit tumourigenesis [6–8]. Although normal human
mammary epithelial cells (HMECs) are exquisitely sensitive
to TGF-b [9•], human breast cancer lines require 10-fold
to 100-fold more TGF-b to produce an antimitogenic
response, and some show complete loss of this effect
[10].
Although loss of growth inhibition by TGF-b in human
cancers can arise through loss of TGF-b production or
through mutational inactivation of the TGF-b receptors and
Smad signalling molecules [11,12], these defects are not
observed in most arrest-resistant cancer lines. This obser-
vation, and the frequent appearance of resistance to more
than one inhibitory cytokine in human tumours [13]
emphasize the importance of the cell cycle effectors of
growth arrest induced by TGF-b as targets for inactivation
in cancer.
TGF-b can either lengthen G1 transit time or cause arrest
in late G1 phase [14]. This cell cycle arrest is usually
reversible [15•,16], but in some cases is associated with
terminal differentiation [17•,18,19]. Because TGF-b
arrests susceptible cells in the G1 phase, a brief review of
cell cycle regulation is presented. This is followed by a
review of the multiple and often, complementary mecha-
nisms that contributing to G1 phase arrest by TGF-b and
of how they are disrupted in breast and other cancers.http://breast-cancer-research.com/content/2/2/116
Cell cycle
Cell cycle progression is governed by cdks, which are
activated by cyclin binding [20,21] and inhibited by the
cdk inhibitors [22,23]. The cdks integrate mitogenic and
growth inhibitory signals and coordinate cell cycle transi-
tions [24,25]. G1 to S phase progression is regulated by
D-type cyclin-, E-type cyclin- and cyclin A-associated cdks
(Fig. 1). B-type cyclin-associated kinases govern G2 and
M phases. Both E-type and D-type cyclin–cdks contribute
to phosphorylation of the retinoblastoma protein (pRb).
Hypophosphorylated pRb binds members of the E2F and
DP1 families of transcription factors, inhibiting these tran-
scriptional activators and actively repressing certain
genes. Phosphorylation of pRb in late G1 phase liberates
free E2F/DP1, allowing activation of genes required for S
phase (for review [26]).
Cyclin-dependent kinase regulation by phosphorylation
Cdk activation requires phosphorylation of a critical threo-
nine (Thr160 in cdk2 and Thr187 in cdk4). There are two
mammalian kinases with in vitro cdk activating kinase
(CAK) activity: cyclin H/cdk7 and the protein encoded by
the human homolog of the Saccharomyces cerevisiae
CAK1, called Cak1p (for review [27]). The specific roles
of these two kinases are somewhat controversial. CAK is
active throughout the cell cycle [20,28], but its access to
cyclin-bound cdks is inhibited by p27 [29]. Cdks are also
negatively regulated by phosphorylation of specific
inhibitory sites [27]. Cdc25 phosphatase family members
must dephosphorylate these inhibitory sites for full cdk
activation. Cdc25A acts on cyclin E-bound cdk2 and is
required for G1 to S phase progression [30].
Cyclin-dependent kinase inhibitors
Two cdk inhibitor families regulate the cell cycle [22,23].
The inhibitor of cdk4 (INK4) family members (p15INK4B,
p16INK4A, p18INK4C and p19INK4D) inhibit specifically cdk4
and cdk6. The p16 gene, or MTS1 (Multi-Tumor Suppres-
sor 1), was discovered as a tumour suppressor that is
deleted in many cancers [31]. Loss of p15, located near
p16 on chromosome 9p, may contribute to loss of G1
arrest by TGF-b (see below).
The kinase inhibitor protein (KIP) family presently consists
of three members, p21WAF1/Cip1, p27Kip1 and p57Kip2. The
KIPs bind and inhibit a broader spectrum of cdks than do
the INK4s. p21 is low in serum-deprived quiescence, but
p21 levels and p21 binding to D-type cyclin–cdk com-
plexes increase in early G1 phase. In addition to regulating
G1 phase progression, p21 acts to coordinate cell cycle
responses to DNA damage [23]. p27Kip1 was first identi-
fied as a heat stable protein whose binding to cyclin
E–cdk2 complexes that was increased by TGF-b, lovo-
statin, or contact inhibition [32•,33,34•,35•,36]. p27 is
high in G0 and early G1 phase and decreases during G1 to
S phase progression. p27 degradation by ubiquitin-
dependent proteolysis [37] is activated by many different
growth factors and may involve ras pathways [38–42].
Although cyclin E–cdk2 phosphorylates p27 on Thr187
leading to its degradation in late G1 phase [43,44], other
kinases may also influence p27 function and/or degrada-
tion. The possibility that mitogenic signalling pathways that
modulate p27 phosphorylation also oppose Smad activa-
tion by TGF-b is the subject of intensive investigation.
Although p21 and p27 inhibit cyclin E–cdk2, they also
function in the assembly and activation of cyclin D–cdk4
and cyclin D–cdk6 complexes. KIP-mediated assembly of
D-type cyclin–cdks in early G1 phase may facilitate activa-
tion of E-type cyclin–cdks through sequestration of KIPs
away from cyclin E complexes [45•,46•].
Mechanisms of cell cycle arrest by TGF-b b
TGF-b b inhibits phosphorylation of the retinoblastoma protein
Cells are sensitive to TGF-b during a discrete period in
early G1 phase, until they reach a ‘restriction point’ 6–10 h
after G0 release [47•,48]. When TGF-b is added after this
critical time point, cells complete the cell cycle but arrest
during the subsequent G1 phase. Laiho et al [47•]
observed that TGF-b inhibits pRb phosphorylation when it
is added in early G1 phase. This key observation sug-
gested that TGF-b was acting before the G1 to S phase
transition to inhibit a pRb kinase, and led to the investiga-
tion of TGF-b effects on cell cycle regulators. These
studies have shown that TGF-b prevents or inhibits G1
cyclin–cdk activation through multiple mechanisms,
leading to pRb dephosphorylation (Fig. 2). E2F activity is
also impaired by TGF-b through a decline in E2F mRNA
levels [49]. The observation that E2F overexpression can
Figure 1
The cell cycle. Cell cycle progression is governed by cyclin-dependent
kinases (cdks), the activities of which are regulated by binding of
cyclins, by phosphorylation and by the cdk inhibitors [the inhibitor of
cdk4 (INK4) family: p15, p16, p18 and p19; and the kinase inhibitor
protein (KIP) family: p21, p27 and p57].Breast Cancer Research    Vol 2 No 2 Donovan and Slingerland
prevent TGF-b-mediated arrest [49] emphasizes the
importance of the effects of TGF-b on pRb and E2F.
TGF-b b downregulates c-myc
In many cell types, TGF-b causes a rapid inhibition of
c-myc transcription [2,16,50]. Transcriptional regulation
by the c-Myc protein is required for G1 to S phase pro-
gression. Downregulation of c-myc by TGF-b is believed
to be important for arrest, because c-myc overexpression
causes TGF-b resistance [2,51•]. Repression of the c-myc
gene by TGF-b may directly or indirectly contribute to the
loss of G1 cyclins [52,53], to downregulation of Cdc25A
[54•] and to the induction of the cdk inhibitor p15 [55•]
(see below).
Effects on G1/S cyclins
TGF-b causes loss of G1 cyclins in a cell-type-dependent
manner. Cyclin A expression is downregulated by TGF-b
in most cell types [32•,56•] and a TGF-b-regulated region
of the cyclin A promoter has been identified [57]. Effects
of TGF-b on cyclin E differ among different cell lines. For
example, in HaCat keratinocytes TGF-b decreases both
mRNA and protein levels of cyclin A and cyclin E, whereas
in HMECs cyclin E mRNA is reduced but protein levels
are not [32•,56•]. Although cyclin D1 levels are decreased
by TGF-b in some cell types, this usually occurs late as a
consequence of arrest [58,59•].
Cooperation between p15 and p27
In epithelial cells, including HMECs, the INK4 and the KIP
proteins collaborate to inhibit D-type cyclin–cdks and
E-type cyclin–cdks to bring about G1 arrest by TGF-b
[60•,61•]. p15INK4B was first cloned as a gene upregulated
by TGF-b [62•] and its induction involves an Sp1 site in
the promoter [63]. TGF-b induces p15INK4B and stabilizes
the p15 protein, leading to p15 binding and inhibition of
cdk4 and cdk6. Cyclin D1 and KIP molecules dissociate
from cdk4 and cdk6, and p27 accumulates in cyclin
E–cdk2 complexes, inhibiting the latter [60•,61•]. A late
downregulation of cyclin D1 and cdk4 follows G1 arrest.
TGF-b appears to actively regulate p27’s affinity for its
targets, independent of p15 function, favouring p27 accu-
mulation in cyclin E complexes [61•].
Upregulation of p21 expression
In normal HMECs, TGF-b affects neither p21 levels, nor
the binding of p21 to target cdks [61•]. In other cell types,
TGF-b induction of p21 plays a role in cdk inhibition
[59•,64•,65] and its upregulation is independent of p53
[64•,66•]. The p21 gene may be a downstream target of
Smad4, because transient overexpression of Smad4
induces  p21 mRNA [67]. Like p15, the p21WAF1/Cip1 gene
promoter contains Sp1 sites that are regulated by TGF-b
in reporter gene assays [63,68]. Other cdk inhibitors, p16,
p18, p19 and p57, have not to date been implicated in
TGF-b-mediated arrest.
Effects on cdk2 phosphorylation
TGF-b also regulates cdk2 phosphorylation. In Mv1Lu
cells, TGF-b inhibits cdk2 in part by inhibiting phosphory-
lation on Thr160 [32•,34•]. p27 can inhibit CAK access to
cyclin-bound cdks in vitro [29]. Thus, TGF-b may prevent
CAK action by increasing the binding of p27 to cyclin
E–cdk2. In HepG2 cells, however, TGF-b inhibits the
enzymatic activity of Cak1p [69], indicating an alternative
mechanism for the inhibition by TGF-b of Thr160 phos-
phorylation of cdk2.
Figure 2
Mechanisms of cell cycle arrest by transforming growth factor (TGF)-b
and their deregulation in cancer. TGF-b receptor activation leads to
Smad2 phosphorylation. Phosphorylated Smad2 then binds Smad4
and the Smad2–Smad4 complex translocates to the nucleus to
modulate transcription. Although p15 and p21 genes are induced and
c-myc and Cdc25A repressed by TGF-b, these may not be direct
effects of Smad2–Smad4 action (dotted lines). TGF-b inhibits G1
cyclin–cyclin-dependent kinases (cdks) by increasing p15 binding to
cdk4 and cdk6 and by increasing p27 (+/– p21) binding to cyclin
E–cdk2, thereby inhibiting retinoblastoma protein (pRb)
phosphorylation. *Components of the TGF-b effector pathway that are
mutated and/or functionally inactivated in human cancers; **molecules
whose activation or overexpression may contribute to TGF-b arrest
resistance.Dephosphorylation of inhibitory sites on cyclin E-bound
cdk2 is required for G1 progression and is required for G1
to S phase progression [30]. In a human breast epithelial
line, TGF-b reduced  Cdc25A expression in association
with an increase in inhibitory cdk phosphorylation [54•].
The effect on Cdc25A expression may be secondary to
the repression by TGF-b of c-myc, because in some cell
types Cdc25A is induced by c-myc [70•].
Loss of TGF-b b mediated G1 arrest in cancer
In nontransformed epithelial cells, TGF-b causes G1 arrest
through downregulation of c-myc, inhibition of the G1 cdks
and hypophosphorylation of pRb. Overlapping or redun-
dant cell cycle controls assure growth arrest. In malig-
nantly transformed cells, however, this redundancy is often
lost and carcinoma-derived cells are usually refractory to
growth inhibition by TGF-b [10]. Indeed, in advanced
cancers, TGF-b may promote tumour growth and metasta-
tic progression [71]. In this part of the discussion, we
review how dysregulation of many different cell cycle
mechanisms abrogate TGF-b arrest in cancer (Fig. 2).
Altered cdk inhibitor expression and function
Dysregulation of the INK4 family may contribute to TGF-b
resistance in cancer. In human tumours, deletion of p15
often accompanies p16 deletion due to their proximity on
chromosome 9p [72–74]. Silencing of p15 through pro-
moter hypermethylation, which is observed in leukaemias,
is associated with loss of TGF-b sensitivity [75,76]. In
other TGF-b-resistant cells, however, p15 protein levels
may increase normally, indicating that, at least in these
lines, a functional p15 is not sufficient to mediate arrest by
TGF-b [65].
Although p15 and p27 cooperate to inhibit the G1
cyclin–cdks in normal cells, neither of these cdk inhibitors
are essential for G1 arrest by TGF-b. p15 is clearly not
essential for TGF-b-mediated G1 arrest, because cells
bearing p15 deletions can respond through upregulation
of p21 and p27 [59•,65], or downregulation of Cdc25A
[54•]. Lymphocytes from p27-null mice can still arrest in
response to TGF-b [77]. Nonetheless, the requirement for
p27 in arrest by TGF-b may differ in normal and trans-
formed cells. Although inhibition of p27 expression
through antisense p27 oligonucleotide transfection did
not abrogate TGF-b-mediated arrest in finite lifespan
HMECs, it did do so in breast cancer-derived lines
(Donovan J, Slingerland J, unpublished data). In normal
cells, multiple redundant pathways cooperate to mediate
arrest, but in cancer cells the progressive loss of other
checkpoints may make p27 indispensable for TGF-b-
mediated arrest.
The antiproliferative role of p27 is frequently disrupted in
human cancers. Although mutations in p27 are rare
[78,79], accelerated proteolysis causes reduced p27
protein in many cancers, including breast, and may con-
tribute to TGF-b resistance [37,80–82]. Less often,
primary tumours may exhibit strong cytoplasmic p27
expression associated with poor prognosis. Cytoplasmic
p27 has been observed in some advanced cancer-derived
lines [83]. Thus, some cancers may express a stable but
inactivated p27. In a TGF-b-resistant HMEC line, we have
observed stable cytoplasmic p27 localization, altered p27
phosphorylation and impaired binding of p27 to cyclin
E–cdk2 (Ciarallo S, Slingerland J, unpublished data). The
elucidation of how of mitogenic signalling pathways alter
p27 inhibitor function may prove important insights into
mechanisms of TGF-b resistance (see below).
Altered KIP function has also been observed in TGF-b-
resistant prostate cancer cells. Although TGF-b caused an
upregulation in p21–cdk2 binding, this kinase was not
inhibited, suggesting that p21 may not function normally in
these cells [84]. Loss of p21 has also been observed in
advanced breast cancers in association with a poor
patient prognosis [85,86]. As for p27, functional inactiva-
tion of p21 could contribute to TGF-b resistance during
breast cancer progression.
Cyclin overexpression and TGF-b b resistance
Overexpression and/or amplification of the cyclin D1 gene is
seen in up to 40% of breast cancers [87,88] and could con-
tribute to TGF-b resistance. Indeed, cyclin D1 transfection of
an oesophageal epithelial line conferred resistance to TGF-b
[89]. Increased cyclin E protein has also been observed in
breast cancers [80,90]. Constitutive overexpression of cyclin
E does not confer TGF-b resistance in Mv1Lu cells, however
(Slingerland J, Reed S, unpublished data). Pathways that link
impaired cyclin degradation with loss of cell cycle responses
to TGF-b have yet to be elucidated.
Cdk4 gene amplification and activating mutation
Although loss of cdk4 does not contribute significantly to
arrest by TGF-b because it occurs after most cells have
entered G1 phase [60•], ectopic cdk4 expression can
abrogate TGF-b-mediated arrest [91•]. The increased
cdk4 level may exceed titration by p15 and, in addition,
sequestration of KIPs away from cyclin E–cdk2 into newly
formed cyclin D–cdk4 complexes may lead to loss of cdk2
inhibition. Overexpression of cdk4 may contribute to
TGF-b resistance in human cancers. Amplification of the
cdk4 gene occurs in primary breast cancers [92] and
dominant active cdk4 mutations have been observed in
human malignant melanoma [31].
Activation of c-myc, and TGF-b b resistance
TGF-b arrest-resistant cells often fail to downregulate
c-myc [65]. Moreover, oncogenic activation of c-myc,
which is seen in a number of human malignancies, includ-
ing breast cancer, may impair TGF-b responsiveness
through a number of mechanisms.
http://breast-cancer-research.com/content/2/2/116Overexpression of c-Myc may increase G1 cyclin levels.
c-Myc may regulate indirectly the expression of cyclins D1,
E and A [52,53]. c-Myc induction of cyclin D1 or cyclin D2
may lead to the sequestration of p27 and p21 away from
cyclin E–cdk2, and thus contribute to cyclin E–cdk2 acti-
vation [93,94]. These effects, however, which are best
demonstrated in fibroblast lines, may not be relevant to
TGF-b resistance in epithelial cells. In Mv1Lu cells, c-myc
overexpression prevents arrest by TGF-b in part by inhibit-
ing p15 induction [55•]. c-Myc effects on D-type cyclin
expression and cyclin D–cdk4 complex formation were not
sufficient to account for loss of the TGF-b response. Thus,
repression of p15 by c-Myc may be important in the
arrest-resistant phenotype.
Additional mechanisms link c-Myc with cyclin E–cdk2 acti-
vation. Overexpression of c-myc can induce a heat labile
factor that binds p27 and inhibits its association with
cyclin E–cdk2 [95]. This effect is independent of p27
degradation. Although in some cell types cyclins D1 and
D2 may be the c-myc-induced inhibitors of p27 [93,94], in
other models the c-myc-induced inhibitor of p27 appears
to be independent of D-type cyclins [95].
Oncogenic activation of c-myc may lead to Cdc25A over-
expression and loss of TGF-b-mediated repression of
Cdc25A [54•]. Overexpression of Cdc25A is observed in
primary breast cancers and is associated with a poor
patient prognosis (Loda M, personal communication). The
increased Cdc25A may represent one of the checkpoints
whose disruption makes subsequent disruption of p27
function more critical during breast cancer progression.
Activation of Ras and its effector pathways and TGF-b b
resistance
Overexpression of activated Ras has been shown to abro-
gate the antimitogenic effects of TGF-b [96]. Mutational
activation of ras is common in many human cancers and
may be linked to TGF-b resistance through a number of
mechanisms. Activated Ras can interfere with TGF-b sig-
nalling by altering Smad2 phosphorylation and signal
transduction [97]. Moreover, Ras activation can increase
cyclin D1 levels through both transcriptional and post-
translational mechanisms [38,98,99]. Ras activation also
accelerates p27 degradation [40,41], in some models
requiring coexpression of Myc [39]. Although ras muta-
tions are not commonly observed in breast cancer, epider-
mal growth factor (EGF) and ErbB2 overexpression are,
and both activate the Ras effector phosphatidylinositol-3
kinase [100]. Oncogenic activation of different ras effector
pathways may abrogate p27 function [41,101], contribut-
ing importantly to TGF-b resistance.
Regulation of other G1 events by TGF-b b
p53 may play a role in the TGF-b response in some cells.
In murine keratinocytes, introduction of mutated p53 led to
TGF-b resistance, and a correlation between p53 mutation
and loss of responsiveness to TGF-b-mediated arrest has
been observed in several cancers [102–104].
Constitutive expression of mdm2 can give rise to TGF-b
resistance. Although the Mdm2 protein binds to p53 to
mediate p53 proteolysis, the effects of Mdm2 on TGF-b
sensitivity appear to be independent of p53 function,
because expression of an Mdm2 mutant that failed to bind
p53 also conferred resistance [105]. Because overexpres-
sion of Mdm2 occurs in about 73% of breast cancers, this
too may play a role in TGF-b resistance in vivo [85,106,
107].
Conclusion
During the past decade the anatomy of cell cycle regula-
tion has been ‘worked out’. TGF-b-induced G1 arrest
occurs through induction of p15 and p21 genes, repres-
sion of the c-myc, Cdc25A, cyclin E and cyclin A genes,
and an increase in the association of p15, p21 and p27
with target cdks. Inactivation of G1 cyclin–cdks leads to
pRb dephosphorylation and E2F inhibition. The discovery
of the Smads as both transducers of TGF-b signalling and
transcriptional regulators has been a major advance in this
field. Mitogenic signalling via ras/mitogen-activated
protein kinase has been shown to interfere with Smad
activation [11]. It will be of interest to ascertain whether
cross-talk with Smads can also negatively regulate com-
ponents of mitogenic signal transduction pathways. How
growth factors and mitogenic pathways influence the tran-
scriptional activation, intracellular localization and degra-
dation of cyclins and cdk inhibitors is only beginning to be
mapped. As these mechanisms are elucidated, we will be
able to move from the myopic view of cyclin–cdk regula-
tion in the nucleus, to a broader three-dimensional view of
cell cycle regulation that encompasses extracellular and
cytoplasmic signalling pathways. The next frontiers lie in
the cytoplasm and at the gateway of the nuclear pore as
we begin to elucidate how TGF-b/Smad signalling inter-
faces with transducers of mitogenic signals to regulate
cyclin–cdk activities.
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